Back to catalogue
№ 022 16 filings · 2021-05-06 → 2025-12-04

ASA INTERNATIONAL GROUP PLC

ASAI
Financial Services Market cap £191m Overall fit 230 /1000

Fundamentally outside the AI thesis — a 13-country microfinance lender with zero AI-receiver exposure and limited capital-light operating leverage. Cheap valuation, improving operations and a positive surprise track record prevent a lower score, but the strategy is built around AI-buildout beneficiaries and this is not one.

Fair value range 250p–330p Mid case · £290m
Absolute upside +52.1% vs current market cap
Conviction 3/5 confidence in undervalued call
Supports the call
  • Three consecutive material beats vs consensus with sequential upgrades
  • Multiple valuation methods (P/E ~5x, P/B ~2x at 46% ROE) all point above current price
  • Going-concern qualification removed at H1 2025; covenant waivers in hand
Limits the call
  • Reported profits highly sensitive to single-currency (Ghana cedi) translation
  • Catalyst >50% controlling stake and thin float limit rerating mechanism
Methodology

Blended P/E (6-8x FY25E) and P/B (2.0-2.5x at 46% ROE)

In one line · bull case

Fast-recovering EM microfinance lender trading at ~5x earnings and 2x book despite 46% ROE, three consecutive consensus beats, and a freshly-removed going-concern qualification.

In one line · biggest risk

Reported profits and equity are dangerously dependent on Ghana cedi stability and on continuing covenant waivers from local lenders, particularly in India.

Drivers
AI beneficiary 5 /100
Microfinance lender with no exposure to AI value chain; Temenos core banking is internal IT spend, not AI revenue.
Operating leverage 45 /100
Cost-income falling (61.7% to 56.4% YoY) but balance-sheet business requires capital and funding to scale, capping multiplier on revenue surprises.
Earnings vs expectations 80 /100
Three consecutive material beats vs consensus (FY23, FY24, H1 25) with two upgrades in H2 2025 alone.
Growth momentum 85 /100
Gross OLP +37% YoY, net profit ~doubled, ROE 46%; clear positive inflection.
Moat 35 /100
Local branch density, group-lending discipline and 50+ lender funding relationships, but microfinance is a competitive low-moat business.
Earnings quality 45 /100
IAS 29 hyperinflation adjustments, FX translation reserve swings (USD +15.5m H1 25 vs -8.7m H1 24) and India deconsolidation reduce clarity.
Management quality 55 /100
Executed recovery from Covid distress and removed going-concern doubt, but governance complicated by Catalyst controlling stake.
Cyclicality 60 /100
EM consumer-lending sensitive to local macro cycles, FX and political risk; 13-country diversification softens but does not eliminate.
Leverage 60 /100
D/E ~3.5x typical for a lending institution; some covenant breaches still outstanding (USD 1.4m without waivers).
Value-trap signals · 4
  • Catalyst Microfinance Investors controls >50% — limited minority leverage
  • ASA India deconsolidation reflects multi-year capital impairment
  • Hyperinflation accounting and FX translation obscure underlying earnings
  • Rule 9 waiver vote in 2025 drew unusually high dissent (~21% against)

ASA International Group plc (ASAI) — Investment Research Note

Executive summary

ASA International is one of the world's largest international microfinance institutions, providing small unsecured loans (predominantly to low-income female entrepreneurs) across 13 countries in South Asia, South East Asia, West Africa and East Africa. The operating trajectory over the period has been a sharp recovery from Covid-era distress (FY 2020 net loss USD 1.4m) through hyperinflation/FX-impaired FY 2023, to a powerful inflection in H1 2025 (net profit nearly doubled to USD 26.8m, ROE 46%, going-concern qualification removed) with management guiding FY 2025 net profit "significantly above" consensus of USD 48.3m 2025-12-04 trading update. The single most important point for valuation is that the shares trade at roughly 5× current-year earnings and ~2× book despite a sub-Saharan/South-Asian franchise generating 46% ROE — but the buyer is taking concentrated emerging-market FX, regulatory and macro risk.

Fair value estimate

Methodology: blended P/E and P/B on FY 2025E underlying net profit, sense-checked against franchise ROE.

Key inputs:

  • 100m shares in issue; equity at 30 Jun 2025 USD 136.2m (~£107m at 1.27 GBP/USD) 2025-09-24 interims.
  • FY 2025E underlying net profit ≥ USD 55m (above the USD 48.3m consensus, per Dec 2025 trading update) = ~£43m.
  • H1 2025 annualised run-rate underlying profit is USD ~48m, but with H2 typically stronger and West/East Africa accelerating.
  • ROE 46% (TTM); cost-income 56.4% and improving; PAR>30 of 2.0% 2025-09-24 interims.

Valuation approaches:

  1. P/E: 6–8× £43m = £258–344m mcap = 258–344p/share.
  2. P/B: at 46% ROE, fair P/B is 2.0–2.5×; on £107m equity = £214–268m = 214–268p.
  3. Through-cycle: blend with a 25% EM/regulatory haircut → £250–320m.

Fair value range: 250p – 330p per share, mid ~290p, implied market cap range £250m – £330m.

Versus current £215.0m mcap (215p), this implies ~35% upside to the mid.

Sector context

  • ICB classification confirmed: Financials / Financial Services. ASAI is a non-deposit-taking (mostly) microfinance lender, more akin to specialty consumer finance than a bank.
  • Quality profile vs typical UK-listed financial peers: above-average growth (loan book +37% YoY), well above-average ROE (46%), but below-average earnings quality owing to FX translation, hyperinflation accounting and EM regulatory volatility.
  • Listed peers (none truly comparable): Bandhan Bank, CreditAccess Grameen (both India), Equity Group Holdings (Kenya), Compartamos / Gentera (Mexico). Most listed microfinance peers trade 1.5–3× book on 15–25% ROEs.

Investment thesis

  • Operating inflection is real and accelerating. Net profit nearly doubled in H1 2025 to USD 26.8m, underlying profit +73%, ROE jumped to 46%, and management has issued two upgrades to consensus in H2 2025 — H1 results lifted FY consensus from USD 16m to USD 37.5m, and the Dec trading update flagged a further "significant" beat of the new USD 48.3m consensus 2025-09-24 interims; 2025-12-04 trading update.
  • Going-concern overhang has been removed. The Apr 2025 FY24 audit carried a material uncertainty over going concern related to covenant breaches; the H1 2025 interims explicitly reversed this conclusion, and the Group raised USD 117.7m in new debt with USD 229m of pipeline 2025-09-24 interims. This is a binary risk that has now cleared.
  • Cheap on every multiple a financial generates. Roughly 5× FY25E earnings and ~2× book despite generating 46% ROE — the disconnect reflects EM risk, controlling-shareholder discount (Catalyst owns >50%) and a thin float, but the direction of all KPIs (PAR, OLP, cost-income, equity base) is favourable. Interim dividend +60% 2025-09-24 interims.

Key risks

  • Concentration in fragile macro/political jurisdictions. Ghana drove almost all of the H1 2025 profit surge thanks to a 32% cedi appreciation; if the cedi reverses, reported earnings will compress sharply. Myanmar (military rule, earthquake), Pakistan, Nigeria and Sri Lanka all carry elevated tail risk 2025-09-24 interims.
  • Credit quality has been worse than reported for India. ASA India is being deconsolidated; PAR>30 of 5.9% and continuing RBI scrutiny on capital ratios and interest rates indicate that the "consolidated" PAR of 2.0% understates underlying volatility. India ECL absorbed USD 25m+ in FY 2021 2024-09-27 interims; 2022-04-26 FY 2021.
  • Capital structure and covenant risk. D/E ratio ~3.5×, debt at holding company USD 67m, and the Group still had USD 18.1m of covenant-breached lines at H1 2025 (USD 1.4m without waivers). A return of covenant problems if PAR deteriorates would re-introduce the going-concern question 2025-09-24 interims.

Operating leverage

ASAI's cost base has a meaningful fixed component: personnel and branch overheads scale with branch count rather than loan volume, and IT/central costs are fixed. The H1 2025 cost-income ratio fell to 56.4% from 61.7% as net interest income outpaced opex growth, and NIM expanded from 32.3% to 39.6% 2025-09-24 interims. However, this is a balance-sheet business: incremental revenue requires incremental loan book, which requires incremental funding (cost of funds 11.2%) and incremental ECL. Loans-per-officer rose from 265 to 273, branches grew only 7% while clients grew 9% and gross OLP grew 37% — that's genuine operating leverage. If revenue surprises 10–20% above expectations (very plausible given current trajectory), operating profit could plausibly rise 30–50% given the cost-income trajectory, but it would not multiply in the manner of a fixed-cost software business. Capacity is not really a "fixed plant" — it is human-capital-driven branch productivity, which has a soft ceiling.

Value-trap signals

  • Catalyst Microfinance Investors holds >50% — minority shareholders sit alongside a controlling sponsor whose interests may not always align (one Rule 9 waiver resolution drew unusually high dissent at the 2025 AGM, just below 80% support) 2025-06-19 AGM result.
  • India operations have shrunk from USD 100m+ OLP to deconsolidated status — a multi-year capital write-down most shareholders have absorbed.
  • Reported earnings include large hyperinflation IAS 29 adjustments (USD +2.5m H1 25, USD –3.5m H1 24) that obscure underlying performance.
  • That said, the trajectory (PAR improving, cost-income improving, going concern removed, dividend growing) does not match a classic value trap — it looks more like a discount tied to genuinely high-uncertainty inputs rather than terminal decline.

Earnings vs expectations

Track record of recent results vs guidance/consensus:

  • FY 2023 (Feb 2024 trading update): Company stated H2 2023 was ahead of expectation; net income would exceed consensus of USD 10.8m. Beat.
  • H1 2024 (Sep 2024): Guided FY 2024 to exceed company consensus of USD 16.0m; outturn USD 28.5m. Material beat.
  • H1 2025 (Sep 2025): Guided FY 2025 to "significantly exceed" consensus of USD 37.5m. Beat that guidance itself — the Dec 2025 update raised the new bar to USD 48.3m and still signalled a significant further beat.
  • Pattern: three consecutive material beats with sequential consensus upgrades. This is one of the cleaner positive surprise series on the UK small-cap board.

Conviction

3 — moderate.

What anchors it: (i) three converging valuation methods (P/E, P/B, residual income at 46% ROE) all point materially above the current price; (ii) operating data — PAR>30, cost-income, equity build, dividend growth, going-concern removal — is consistently favourable; (iii) management has beaten guidance multiple times.

What limits it: (i) reported earnings are heavily exposed to a single currency (Ghana cedi) reversing; (ii) ASA India deconsolidation is incomplete and underlying credit risk in low-margin emerging markets is hard to model with precision; (iii) controlling-shareholder structure and limited free float make the rerating timing uncertain — the stock can stay cheap.

Filings consulted · 18

Every document the LLM read for this note. Click any row to open the source.

  1. 2025-12-04Trading Update2025-12-04_9274650_trading-update.md0.85
  2. 2025-09-242025 Interim Results2025-09-24_9127385_2025-interim-results.md0.77
  3. 2025-06-19Result OF Agm2025-06-19_8938925_result-of-agm.md0.26
  4. 2024-12-05Interim Dividend Declaration2024-12-05_8591491_interim-dividend-declaration.md0.20
  5. 2024-09-272024 Interim Results2024-09-27_8443237_2024-interim-results.md0.58
  6. 2024-06-20Result OF Agm2024-06-20_8270429_result-of-agm.md0.20
  7. 2024-06-06Notice OF Agm2024-06-06_8245127_notice-of-agm.md0.20
  8. 2024-02-282023 Year End Trading Update2024-02-28_8059685_2023-year-end-trading-update.md0.38
  9. 2023-06-15Result OF Agm2023-06-15_7577227_result-of-agm.md0.14
  10. 2023-05-172022 Annual Report Amp Accounts And Notice OF Agm2023-05-17_7531665_2022-annual-report-amp-accounts-and-notice-of-agm.md0.24
  11. 2023-02-24Year End Trading Update2023-02-24_7233747_year-end-trading-update.md0.21
  12. 2022-06-22Result OF Agm2022-06-22_7066558_result-of-agm.md0.07
  13. 2022-04-262021 Full Year Results2022-04-26_7041686_2021-full-year-results.md0.25
  14. 2022-02-24Year End Trading Update2022-02-24_6926185_year-end-trading-update.md0.21
  15. 2021-09-21Interim Results2021-09-21_6512424_interim-results.md0.23
  16. 2021-06-30Result OF Agm2021-06-30_6472147_result-of-agm.md0.07
  17. 2021-06-012020 Annual Report And Accounts2021-06-01_6562472_2020-annual-report-and-accounts.md0.24
  18. 2021-05-06Notification OF 2020 Full Year Results And Agm2021-05-06_6249512_notification-of-2020-full-year-results-and-agm.md0.10

This research note was authored by a large language model after reading 16 regulatory filings published between 2021-05-06 and 2025-12-04. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.